Tiffanie Benway

This inventor holds 14 USPTO granted patents and 10 published patent applications, plus 5 CIPO patents and 9 EPO patents. Top assignees: Cybin UK Ltd, Small Pharma Ltd. Active years: 2022-2026.

USPTO Granted Patents = 14 (Patent Applications = 10)

% Patents Active = 100.0

CIPO Patents = 5 (Patent Applications = 7)

EPO Patents = 9 (Patent Applications = 14)

Average Co-Inventor Count = 4.7

ph-index = 5

Forward Citations = 59(Granted Patents)

Company Filing History:

Years Active: 2022-2026

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12649718 - Synthesis of n,n-dimethyltryptamine-type compounds, methods, and uses preliminary class 548 (2026-06-09),

2. 12521370 - Inhalable formulations (2026-01-13),

3. 12318477 - Injectable and inhalable formulations (2025-06-03),

4. 12251371 - Deuterated or partially deuterated N,N-dimethyltryptamine compounds (2025-03-18),

5. 12157723 - Compounds (2024-12-03),

6. 12084417 - Synthesis of N,N-dimethyltryptamine-type compounds, methods, and uses (2024-09-10),

7. 12076311 - Therapeutic compositions comprising deuterated or partially deuterated N,N-dimethyltryptamine compounds (2024-09-03),

8. 12042564 - Therapeutic solid dosage forms (2024-07-23),

9. 11773062 - Deuterated compounds (2023-10-03),

10. 11771681 - Therapeutic compounds (2023-10-03),

11. 11660289 - Deuterated or partially deuterated N,N-dimethyltryptamine compounds (2023-05-30),

12. 11643390 - Synthesis of N,N-dimethyltryptamine-type compounds, methods, and uses (2023-05-09),

13. 11578039 - Compounds (2023-02-14),

14. 11471417 - Deuterated N,N-dimethyltryptamine compounds (2022-10-18),

Title: Tiffanie Benway: Innovator in Pharmaceutical Formulations

Introduction

Tiffanie Benway is a prominent inventor based in London, GB. She has made significant contributions to the field of pharmaceutical formulations, particularly in the development of innovative therapies for psychiatric and neurological disorders. With a total of 14 patents to her name, her work is paving the way for new treatment options.

Latest Patents

Benway's latest patents include groundbreaking formulations that focus on injectable and inhalable methods. One of her notable inventions relates to aqueous pharmaceutical formulations that comprise a salt of an optionally substituted dimethyltryptamine compound. These formulations are designed for use in psychedelic-assisted therapy and can be administered through intramuscular injection or nebulized inhalation. The formulations are stable, clinically acceptable, and have potential applications in treating various psychiatric or neurological disorders. Another significant patent involves deuterated or partially deuterated N,N-dimethyltryptamine compounds, which offer tailored therapeutic effects through varying compositions.

Career Highlights

Throughout her career, Tiffanie has worked with notable companies such as Small Pharma Ltd and Cybin UK Ltd. Her innovative approach and dedication to research have established her as a key figure in the pharmaceutical industry.

Collaborations

Tiffanie has collaborated with esteemed colleagues, including Peter Rands and Zelah Joel, further enhancing her contributions to the field.

Conclusion

Tiffanie Benway's work exemplifies the spirit of innovation in pharmaceutical research. Her patents and collaborations are set to make a lasting impact on the treatment of psychiatric and neurological disorders.